Extension of PUSU Deadline

THIS IS AN ANNOUNCEMENT UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER MIGHT BE MADE.

Oxford Biomedica plc

Extension of PUSU Deadline

On 14 January 2026, Oxford Biomedica plc ("OXB" or the "Company") (LSE: OXB) confirmed it had received an unsolicited approach from EQT X EUR SCSp and EQT X USD SCSp each represented by its manager (gérant), EQT Fund Management S.à r.l. (collectively referred to as "EQT") regarding a possible cash offer for the entire issued and to be issued ordinary share capital of the Company (the "Possible Offer Announcement"). The Board further confirmed it had engaged in preliminary discussions with EQT to explore whether EQT could make a proposal at a level that the Board would be minded to recommend.

Preliminary discussions between the parties remain ongoing and in accordance with Rule 2.6(c) of the Code, the Board of OXB has requested, and the Panel on Takeovers and Mergers (the "Takeover Panel") has consented to, an extension to the date by which EQT is required either to announce a firm intention to make an offer for OXB in accordance with Rule 2.7 of the Code or to announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. Such announcement must now be made by not later than 5.00pm on 25 February 2026. This deadline can be extended with the consent of the Takeover Panel.

There can be no certainty that an offer will be made, nor as to the terms at which a firm offer might be made.

A further announcement will be made when appropriate. In the meantime, OXB shareholders are urged to take no action.

PUBLICATION OF THIS ANNOUNCEMENT

ADDITIONAL INFORMATION

UK MAR